Good afternoon :)
$
₹
Harmony Biosciences Holdings

Harmony Biosciences Holdings

HRMY

NASDAQ
Asset Logo

Harmony Biosciences Holdings

HRMY

NASDAQ
$34.456.93% (-2.56)
$
₹
$34.456.93% (-2.56)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $2.2B the stock is ranked 2090

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

12.22
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.25
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$3.1
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

18.88%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 12 analysts reports

Buy
8 analysts
Hold
3 analysts
Sell
1 analyst

Price Upside

+29.88%

Earnings Growth

+55.94%

Rev. Growth

+18.17%

See Detailed Forecast

Company Profile

Company Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
46.00
46.00
1Y Return
56.59%
56.59%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
41.05
41.05
1Y Return
48.81%
48.81%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
149.85
149.85
1Y Return
79.29%
79.29%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
30.82
30.82
1Y Return
31.97%
31.97%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.39
26.39
1Y Return
11.26%
11.26%
Buy Reco %
75.00
75.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 29.88% growth, versus a trailing 3-year CAGR of 14.09%.

2026
Current$37.02Baseline
Analyst Target - 1 year
Target$48.08+29.88%

All values in $

202220232024202520262027$36.95$44.84$52.72Target+29.88%
2026
Current$37.02Baseline
Analyst Target - 1 year
Target$48.08+29.88%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 18.17% growth, versus a trailing 3-year CAGR of 25.64%.

2025
Current$868.45Baseline
Forecast for Dec 2026
High$1,037.8+19.5%
Average$1,026.25+18.17%
Low$1,000+15.15%

All values in $ Million

202120222023202420252026305.44437.85582.02714.73868.45Low+15.15%Average+18.17%High+19.5%
2025
Current$868.45Baseline
Forecast for Dec 2026
High$1,037.8+19.5%
Average$1,026.25+18.17%
Low$1,000+15.15%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 55.94% growth, versus a trailing 3-year CAGR of 5.89%.

2025
Current$3.35Baseline
Forecast for Dec 2026
High$5.31+58.68%
Average$5.22+55.94%
Low$5.13+53.2%

All values in $

2021202220232024202520260.832.822.844.043.35Low+53.2%Average+55.94%High+58.68%
2025
Current$3.35Baseline
Forecast for Dec 2026
High$5.31+58.68%
Average$5.22+55.94%
Low$5.13+53.2%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

239.4
50.8
243.7
22.4
215.3
32.4
261.2
75.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue154.61172.81186.03201.26184.73200.48239.45243.77215.38261.28
Net Income38.3311.5946.0949.4745.5639.7750.8622.4832.4875.43
Net Profit Margin24.79%6.70%24.77%24.58%24.66%19.83%21.24%9.22%15.08%28.86%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Harmony Biosciences Holdings 12.222.25-
Eli Lilly and Company46.0031.351.35
Johnson & Johnson41.058.063.07
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare HRMY with any stock or ETF
Compare HRMY with any stock or ETF
Comparing from
HRMY
LLY
JNJ
Loading...

Frequently asked questions

  1. Harmony Biosciences Holdings (HRMY) share price today is $34.45 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $35.73 and a day low of $32.77.

  2. Harmony Biosciences Holdings stock trades on NASDAQ under the ticker symbol HRMY.

  3. Harmony Biosciences Holdings's market capitalization is $2.2B as of November 5, 2026 at 2:29 AM IST.

  4. Harmony Biosciences Holdings's price-to-earnings (P/E) ratio is 12.22 as of November 4, 2026.

  5. Harmony Biosciences Holdings's price-to-book (P/B) ratio is 2.25 as of November 4, 2026.

  6. Yes, You can buy Harmony Biosciences Holdings shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Harmony Biosciences Holdings shares in three steps: 1. Search Harmony Biosciences Holdings on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Harmony Biosciences Holdings trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Harmony Biosciences Holdings (HRMY) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.2902 shares at the current price of $34.45.

Loading...